A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Incyte Corporation
Incyte Corporation
Prelude Therapeutics
Incyte Corporation
Incyte Corporation
Incyte Corporation
Washington University School of Medicine
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
University of Chicago
Stanford University
Mayo Clinic
Hangzhou GluBio Pharmaceutical Co., Ltd.
AbbVie
City of Hope Medical Center
American Regent, Inc.
University of Virginia
University of Alabama at Birmingham
Icahn School of Medicine at Mount Sinai
AbbVie
Epigenetix, Inc.
Vanderbilt-Ingram Cancer Center
Fox Chase Cancer Center
Newave Pharmaceutical Inc
OHSU Knight Cancer Institute
Dartmouth-Hitchcock Medical Center
AbbVie
Herlev Hospital
Lynk Pharmaceuticals Co., Ltd
Prelude Therapeutics
Icahn School of Medicine at Mount Sinai
Taiga Biotechnologies, Inc.
University of Rochester
Medigene AG
H. Lee Moffitt Cancer Center and Research Institute
Case Comprehensive Cancer Center
Novartis
Case Comprehensive Cancer Center
Daiichi Sankyo
Mayo Clinic
University of Pittsburgh
Northwestern University
Stanford University
Wake Forest University Health Sciences
Eli Lilly and Company
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
California Cancer Consortium
Massachusetts General Hospital
University of Louisville